William J. Peters Sells 7,426 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) CFO William J. Peters sold 7,426 shares of Amphastar Pharmaceuticals stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total value of $386,523.30. Following the transaction, the chief financial officer now directly owns 94,103 shares of the company’s stock, valued at approximately $4,898,061.15. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Amphastar Pharmaceuticals Trading Up 4.8 %

Amphastar Pharmaceuticals stock opened at $48.31 on Friday. The stock has a 50-day moving average price of $48.44 and a 200 day moving average price of $44.21. Amphastar Pharmaceuticals, Inc. has a 52 week low of $36.56 and a 52 week high of $65.92. The stock has a market cap of $2.35 billion, a PE ratio of 16.10, a P/E/G ratio of 1.02 and a beta of 0.82. The company has a current ratio of 3.52, a quick ratio of 2.63 and a debt-to-equity ratio of 0.82.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings data on Wednesday, August 7th. The company reported $0.85 earnings per share for the quarter, beating analysts’ consensus estimates of $0.75 by $0.10. Amphastar Pharmaceuticals had a net margin of 21.80% and a return on equity of 26.96%. The business had revenue of $182.39 million during the quarter, compared to analyst estimates of $171.29 million. Equities research analysts predict that Amphastar Pharmaceuticals, Inc. will post 3.67 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Piper Sandler cut their price target on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating for the company in a research note on Thursday, August 8th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Thursday, August 8th. Finally, StockNews.com cut shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $63.00.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. TD Asset Management Inc increased its stake in Amphastar Pharmaceuticals by 67.4% in the second quarter. TD Asset Management Inc now owns 1,691,569 shares of the company’s stock valued at $67,663,000 after purchasing an additional 680,976 shares during the last quarter. Boston Trust Walden Corp purchased a new position in shares of Amphastar Pharmaceuticals during the 3rd quarter worth about $26,189,000. Millennium Management LLC boosted its position in shares of Amphastar Pharmaceuticals by 84.6% in the second quarter. Millennium Management LLC now owns 738,748 shares of the company’s stock worth $29,550,000 after acquiring an additional 338,653 shares during the last quarter. Epoch Investment Partners Inc. grew its holdings in Amphastar Pharmaceuticals by 35.1% in the second quarter. Epoch Investment Partners Inc. now owns 1,078,852 shares of the company’s stock valued at $43,154,000 after purchasing an additional 280,390 shares during the period. Finally, Marshall Wace LLP purchased a new stake in Amphastar Pharmaceuticals in the second quarter valued at approximately $9,085,000. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.